APOA2 and pachyonychia congenita: According to the results, a greater accuracy to discriminate patients with early-stage PC from healthy controls and to identify patients at high risk for PC was achieved by using CA19-9 in combination with Apo-AII-ATQ/AT than by using CA19-9 alone.